Literature DB >> 35837182

The efficacy and safety of continuous intra-arterial infusion neoadjuvant chemotherapy with surgery for locally advanced gastric cancer: a preliminary pilot study.

Bin Li1, Rui Tang1, Guangqiang Zhang1, Jingkai Cheng1, Ming Chao1, Kefeng Ding2.   

Abstract

Background: Neoadjuvant chemotherapy (NAC) followed by R0 resection is regarded as a standard treatment strategy for locally advanced gastric cancer (GC); however, the response to systemic chemotherapy remains unsatisfactory. Continuous intra-arterial infusion chemotherapy (CAIC) is a new method, compared with systematic chemotherapy, it can deliver chemotherapy drugs more accurately, so as to achieve higher surgical conversion rate. This study aimed to explore the efficacy and safety of CAIC in locally advanced GC patients.
Methods: In this retrospective pilot study, four patients with histologically confirmed locally advanced GC were identified from a tertiary hospital between May 2018 and December 2018. Clinic stage was belonged to T4N1-3M0 in all cases with potential probability for surgery. All cases received three cycles of NAC by CAIC with oxaliplatin (100 mg on day 1) plus oral S-1 (80 mg/m2/day twice daily for 14 days) (SOX). Contrast-enhanced computed tomography (CT) scans and pathological examinations were performed to evaluate chemotherapeutic response based on the tumor regression grade (TRG) and post-neoadjuvant pathological Tumor Node Metastasis (ypTNM) staging. All cases were regularly followed up with face-to-face interviews at outpatient, abdominal enhanced CT scan and serum tumor markers were be requested at 3-month intervals for up to 1 year postoperatively.
Results: The obstruction was significantly alleviated after three cycles of CAIC. Contrast-enhanced CT scans showed decreased tumor volume to some extent, along with lymph node shrinkage after treatment. Radical (R0) resection was achieved in all cases. Histopathological analysis showed tumor downstaging in three cases and upstaging in one case. The tumor response to treatment demonstrated TRG1a in one case, TRG1b in one case, and TRG2 in two cases, with an overall tumor regression rate of 100%. No obvious adverse events or perioperative complications were observed during or following treatment. All cases were alive without tumor recurrence or progression after the 1-year postoperative follow-up. Conclusions: Our study may shed light on super-selective CAIC as an effective method for improving the NAC response in locally advanced GC. Future studies with a larger sample sizes and long-term outcomes are required for a final conclusion. 2022 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Locally advanced gastric cancer; SOX regimen; continuous intra-arterial infusion; neoadjuvant chemotherapy (NAC)

Year:  2022        PMID: 35837182      PMCID: PMC9274046          DOI: 10.21037/jgo-22-304

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  20 in total

1.  Impact of ypT, ypN, and Adjuvant Therapy on Survival in Gastric Cancer Patients Treated with Perioperative Chemotherapy and Radical Surgery.

Authors:  Felipe José Fernández Coimbra; Victor Hugo F de Jesus; Héber S C Ribeiro; Alessandro L Diniz; André Luís de Godoy; Igor Correia de Farias; Tiago Felismino; Celso A L Mello; Maria Fernanda Almeida; Maria Dirlei F S Begnami; Emmanuel Dias-Neto; Rachel S P Riechelmann; Wilson L da Costa
Journal:  Ann Surg Oncol       Date:  2019-06-20       Impact factor: 5.344

2.  Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandard's Tumor Regression Grade (TRG) in gastric adenocarcinoma.

Authors:  Simon Derieux; Magali Svrcek; Sarah Manela; Christine Lagorce-Pages; Anne Berger; Thierry André; Julien Taieb; François Paye; Thibault Voron
Journal:  Dig Liver Dis       Date:  2019-08-16       Impact factor: 4.088

3.  [Application of regional arterial infusion chemotherapy in short-term neoadjuvant chemotherapy for advanced gastric cancer].

Authors:  Zhenfeng Wu; Wenqiang Zhu; Qinhong Cao; Zhiwei Chen; Xiaoyu Wu; Che Chen; Zhe Xu; WeiSu Li; Xuequan Yao; Fukun Liu
Journal:  Zhonghua Wei Chang Wai Ke Za Zhi       Date:  2014-11

Review 4.  Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies.

Authors:  G Tomasello; F Petrelli; M Ghidini; E Pezzica; R Passalacqua; F Steccanella; L Turati; G Sgroi; S Barni
Journal:  Eur J Surg Oncol       Date:  2017-03-18       Impact factor: 4.424

5.  An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis.

Authors:  Hiroshi Katayama; Akira Tsuburaya; Junki Mizusawa; Kenichi Nakamura; Hitoshi Katai; Hiroshi Imamura; Atsushi Nashimoto; Norimasa Fukushima; Takeshi Sano; Mitsuru Sasako
Journal:  Gastric Cancer       Date:  2019-07-01       Impact factor: 7.370

6.  Evaluation of Surefire's precision direct-to-tumor embolization device to augment therapeutic response to intra-arterial, liver-directed therapies for patients with primary and secondary liver cancers.

Authors:  Alexander Y Kim; Akemi Miller
Journal:  Expert Rev Med Devices       Date:  2016-03-25       Impact factor: 3.166

7.  Application of FLEEOX Preoperative Chemotherapy via Intra-arterial and Intravenous Administration in Treatment of Unresectable Locally Advanced Gastric Cancer.

Authors:  Qi He; Yang Li; Long Ma; Xiang Ji; Guoli Li
Journal:  J Gastrointest Surg       Date:  2016-04-25       Impact factor: 3.452

8.  Perfusion CT - A novel quantitative and qualitative imaging biomarker in gastric cancer.

Authors:  Joanna Kruk-Bachonko; Witold Krupski; Michał Czechowski; Ewa Kurys-Denis; Przemysław Mądro; Jadwiga Sierocińska-Sawa; Andrzej Dąbrowski; Grzegorz Wallner; Tomasz Skoczylas
Journal:  Eur J Radiol       Date:  2017-09-21       Impact factor: 3.528

9.  Tumor blood supply may predict neoadjuvant chemotherapy response and survival in patients with gastric cancer.

Authors:  Xiang Ji; Qiaoyun Yang; Hui Qin; Jie Zhou; Wenming Liu
Journal:  J Int Med Res       Date:  2019-05-01       Impact factor: 1.671

10.  Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer.

Authors:  Birendra Kumar Sah; Benyan Zhang; Huan Zhang; Jian Li; Fei Yuan; Tao Ma; Min Shi; Wei Xu; Zhenglun Zhu; Wentao Liu; Chao Yan; Chen Li; Bingya Liu; Min Yan; Zhenggang Zhu
Journal:  Nat Commun       Date:  2020-11-30       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.